L
Lillian M. Fuller
Researcher at University of Texas MD Anderson Cancer Center
Publications - 69
Citations - 3379
Lillian M. Fuller is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Radiation therapy & Combination chemotherapy. The author has an hindex of 31, co-authored 69 publications receiving 3331 citations. Previous affiliations of Lillian M. Fuller include Texas Medical Center & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Results of MIME salvage regimen for recurrent or refractory lymphoma
Fernando Cabanillas,Fredrick B. Hagemeister,Peter McLaughlin,William S. Velasquez,Shirley Riggs,Lillian M. Fuller,Terry K. Smith +6 more
TL;DR: The methyl-gag was added to ifosfamide, methotrexate, and etoposide (VP-16) combination, which has been effective in the treatment of patients with recurrent or refractory lymphoma, but cannot be considered curative in the majority of cases.
Journal ArticleDOI
Recovery of spermatogenesis after treatment for Hodgkin's disease: limiting dose of MOPP chemotherapy.
M F da Cunha,Marvin L. Meistrich,Lillian M. Fuller,J H Cundiff,Fredrick B. Hagemeister,W. S. Velasquez,P. McLaughlin,Shirley Riggs,Fernando Cabanillas,P G Salvador +9 more
TL;DR: The results suggest that three cycles of MOPP chemotherapy represent a maximum exposure compatible with the recovery of spermatogenesis and that patients who did not receive pelvic irradiation appeared to have greater recovery rates.
Journal ArticleDOI
Magnetic resonance imaging in the staging of solitary plasmacytoma of bone.
Lia A. Moulopoulos,Meletios A. Dimopoulos,Donna M. Weber,Lillian M. Fuller,Herman I. Libshitz,Raymond Alexanian +5 more
TL;DR: Four of 12 patients considered to have a SBP by standard criteria may have been understaged, because MR imaging showed additional marrow abnormalities consistent with myeloma, and MR imaging of the spine may contribute to the initial staging of SBP.
Journal ArticleDOI
Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma.
S Jagannath,W S Velasquez,Susan L. Tucker,Lillian M. Fuller,P. McLaughlin,John T. Manning,L. B. North,Fernando Cabanillas +7 more
TL;DR: The measure of tumor burden proposed herein, along with LDH level, can be used for developing treatment programs, and for meaningful comparison of different treatment regimens, as well as assessment of prognosis.
Journal ArticleDOI
Long-term results with radiotherapy for stage I–II follicular lymphomas
Richard B. Wilder,Dan Jones,Susan L. Tucker,Lillian M. Fuller,Chul S. Ha,Peter McLaughlin,Mark A. Hess,Fernando Cabanillas,James D. Cox +8 more
TL;DR: RT can cure approximately one half of Stage I and one quarter of Stage II, World Health Organization Grade 1 or 2 follicular lymphomas and there is a trend toward a higher incidence of late complications with doses of >30.8 Gy, and there are no significant differences in overall survival between those treated with extended-field RT and those treating with involved- field RT or regional RT.